{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:43:31Z","timestamp":1780605811549,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,24]]},"DOI":"10.7759\/cureus.86646","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T10:05:42Z","timestamp":1750759542000},"source":"Crossref","is-referenced-by-count":1,"title":["Bilateral Multiple Chalazia After Adalimumab Therapy for Uveitis Associated With Generalized Pustular Psoriasis: A Case Report"],"prefix":"10.7759","author":[{"given":"Azusa","family":"Yamagishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kaiho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Yotsukura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000562","article-title":"Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics","volume":"30","author":"Thomas AS","year":"2019","unstructured":"Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019, 30:138-50. 10.1097\/ICU.0000000000000562","journal-title":"Curr Opin Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1491605","article-title":"Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials","volume":"27","author":"Goto H","year":"2019","unstructured":"Goto H, Zako M, Namba K, et al.. Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm. 2019, 27:40-50. 10.1080\/09273948.2018.1491605","journal-title":"Ocul Immunol Inflamm"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2023.2279014","article-title":"Chalazion treatment: a concise review of clinical trials","volume":"49","author":"Tashbayev B","year":"2024","unstructured":"Tashbayev B, Chen X, Utheim TP. Chalazion treatment: a concise review of clinical trials. Curr Eye Res. 2024, 49:109-18. 10.1080\/02713683.2023.2279014","journal-title":"Curr Eye Res"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.3329\/fmcj.v9i2.25676","article-title":"Comparative study of surgical treatment of chalazion","volume":"9","author":"Hossain KA","year":"2015","unstructured":"Hossain KA, Rashid MA, Islam AR. Comparative study of surgical treatment of chalazion. Faridpur Med Coll J. 2015, 9:68-9.","journal-title":"Faridpur Med Coll J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i17.3253","article-title":"Ocular rosacea without facial erythema involvement manifesting as bilateral multiple recurrent chalazions: a case report","volume":"12","author":"Han XM","year":"2024","unstructured":"Han XM, Zhou YM, Cen LS. Ocular rosacea without facial erythema involvement manifesting as bilateral multiple recurrent chalazions: a case report. World J Clin Cases. 2024, 12:3253-8. 10.12998\/wjcc.v12.i17.3253","journal-title":"World J Clin Cases"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10062","article-title":"A case report on bortezomib-induced bilateral chalazion","volume":"12","author":"Paravathaneni M","year":"2020","unstructured":"Paravathaneni M, Thota V, Mulla S, Thirumaran R, Thar YY. A case report on bortezomib-induced bilateral chalazion. Cureus. 2020, 12:e10062. 10.7759\/cureus.10062","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/112067210401400311","article-title":"Giant chalazia in the hyperimmunoglobulinemia E (hyper-IgE) syndrome","volume":"14","author":"Crama N","year":"2004","unstructured":"Crama N, Toolens AM, van der Meer JW, Cruysberg JR. Giant chalazia in the hyperimmunoglobulinemia E (hyper-IgE) syndrome. Eur J Ophthalmol. 2004, 14:258-60. 10.1177\/112067210401400311","journal-title":"Eur J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S263146","article-title":"Demography and clinical features of chalazion among patients seen at a multi-tier eye care network in India: an electronic medical records driven big data analysis report","volume":"14","author":"Das AV","year":"2020","unstructured":"Das AV, Dave TV. Demography and clinical features of chalazion among patients seen at a multi-tier eye care network in India: an electronic medical records driven big data analysis report. Clin Ophthalmol. 2020, 14:2163-8. 10.2147\/OPTH.S263146","journal-title":"Clin Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318420","article-title":"Prevalence and risk factors for chalazion in an older veteran population","volume":"106","author":"Patel S","year":"2022","unstructured":"Patel S, Tohme N, Gorrin E, Kumar N, Goldhagen B, Galor A. Prevalence and risk factors for chalazion in an older veteran population. Br J Ophthalmol. 2022, 106:1200-5. 10.1136\/bjophthalmol-2020-318420","journal-title":"Br J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3126\/nepjoph.v10i1.21661","article-title":"Intralesional triamcinolone acetonide (TA) versus incision and curettage (I & C) for medium and large size chalazia","volume":"10","author":"Singhania R","year":"2018","unstructured":"Singhania R, Sharma N, Vashisht S, Dewan T. Intralesional triamcinolone acetonide (TA) versus incision and curettage (I & C) for medium and large size chalazia. Nepal J Ophthalmol. 2018, 10:3-10. 10.3126\/nepjoph.v10i1.21661","journal-title":"Nepal J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.04.003","article-title":"Paradoxical reactions to biologic therapy in psoriasis: a review of the literature","volume":"109","author":"Munera-Campos M","year":"2018","unstructured":"Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermo Sifiliogr. 2018, 109:791-800. 10.1016\/j.ad.2018.04.003","journal-title":"Actas Dermo Sifiliogr"},{"key":"ref12","article-title":"Reactive granulomatous dermatitis during anti-TNF therapy: a case report and review of the literature","volume":"4","author":"Cassone G","year":"2017","unstructured":"Cassone G, Citriniti G, Sebastiani M, Manfredi A, Cesinaro AM, Ferri C. Reactive granulomatous dermatitis during anti-TNF therapy: a case report and review of the literature. Clin Med Rev Case Rep. 2017, 4:172.","journal-title":"Clin Med Rev Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative","volume":"125","author":"Dick AD","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, et al.. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology. 2018, 125:757-73. 10.1016\/j.ophtha.2017.11.017","journal-title":"Ophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16583","article-title":"Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020","volume":"50","author":"Kamiya K","year":"2023","unstructured":"Kamiya K, Ohtsuki M. Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020. J Dermatol. 2023, 50:3-11. 10.1111\/1346-8138.16583","journal-title":"J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1767590","article-title":"Switching biologics in psoriasis - practical guidance and evidence to support","volume":"13","author":"Tsai YC","year":"2020","unstructured":"Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020, 13:493-503. 10.1080\/17512433.2020.1767590","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00486-1","article-title":"Certolizumab pegol treatment in patients with axial-spondyloarthritis-associated acute anterior uveitis: A narrative review","volume":"9","author":"van der Horst-Bruinsma IE","year":"2022","unstructured":"van der Horst-Bruinsma IE, Robinson PC, Favalli EG, et al.. Certolizumab pegol treatment in patients with axial-spondyloarthritis-associated acute anterior uveitis: A narrative review. Rheumatol Ther. 2022, 9:1481-97. 10.1007\/s40744-022-00486-1","journal-title":"Rheumatol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237388","article-title":"Comparative study of adalimumab, infliximab and certolizumab pegol in the treatment of cystoid macular edema due to Beh\u00e7et\u2019s disease","volume":"13","author":"Barroso-Garc\u00eda N","year":"2024","unstructured":"Barroso-Garc\u00eda N, Mart\u00edn-Varillas JL, Ferraz-Amaro I, et al.. Comparative study of adalimumab, infliximab and certolizumab pegol in the treatment of cystoid macular edema due to Beh\u00e7et\u2019s disease. J Clin Med. 2024, 13:10.3390\/jcm13237388","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002693","article-title":"Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients","volume":"8","author":"Mart\u00edn-Varillas JL","year":"2022","unstructured":"Mart\u00edn-Varillas JL, Sanchez-Bilbao L, Calvo-R\u00edo V, et al.. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients. RMD Open. 2022, 8:e002693. 10.1136\/rmdopen-2022-002693","journal-title":"RMD Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16704","article-title":"The use of certolizumab pegol to successfully treat generalized pustular psoriasis combined with psoriatic uveitis","volume":"50","author":"Yatsuzuka K","year":"2023","unstructured":"Yatsuzuka K, Matsumoto T, Sakane Y, Fukaura R, Takeichi T, Akiyama M, Murakami M. The use of certolizumab pegol to successfully treat generalized pustular psoriasis combined with psoriatic uveitis. J Dermatol. 2023, 50:e175-6. 10.1111\/1346-8138.16704","journal-title":"J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372388-bilateral-multiple-chalazia-after-adalimumab-therapy-for-uveitis-associated-with-generalized-pustular-psoriasis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T10:05:42Z","timestamp":1750759542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372388-bilateral-multiple-chalazia-after-adalimumab-therapy-for-uveitis-associated-with-generalized-pustular-psoriasis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.86646","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}